Related Experiment Video

Updated: May 12, 2026

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
08:52

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

Tumour vasculature targeting agents in hybrid/conjugate drugs

E M Prokopiou1, S A Ryder, J J Walsh

  • 1School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland.

Angiogenesis
|April 2, 2013
PubMed

Insights

Functional hybrids combining cancer drug components offer a promising strategy for targeting tumour vasculature. These novel agents, including RGD/NGR-conjugates and antibody-drug conjugates, show potential in preclinical studies for enhanced anti-cancer therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Tumour growth and metastasis depend on a robust blood supply.
  • Targeting tumour vasculature is a key strategy in cancer drug discovery.
  • Current anti-angiogenic and vascular disrupting agents often require combination therapy for efficacy.

Purpose of the Study:

  • To review functional hybrid and conjugate-based approaches targeting tumour angiogenic/vasculature pathways.
  • To highlight preclinical evaluations of these novel anti-cancer agents.
  • To discuss the future directions and applications of hybrid drug development.

Main Methods:

  • Review of literature on functional hybrids and conjugates for tumour vasculature targeting.
  • Emphasis on preclinical evaluation of specific conjugate types.
  • Analysis of RGD/NGR-conjugates, heparin-related hybrids, and antibody-drug conjugates.

Main Results:

  • Functional hybrids integrating tumour vasculature targeting components show promise.
  • Preclinical data for RGD/NGR-conjugates, heparin-related hybrids, and antibody-drug conjugates are presented.
  • These hybrid approaches aim to enhance anti-cancer efficacy.

Conclusions:

  • Hybrid and conjugate-based strategies represent a novel concept in cancer drug design.
  • Further development and evaluation are needed to realize the full potential of these agents.
  • Discussion of benefits and shortcomings informs future research directions.

More Related Videos

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics12:09

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

Published on: June 16, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...